Urology Department, Hospital Universitario 12 de Octubre, Spain.
Urology Department, Complejo Hospitalario Universitario de A Coruña, Spain.
Actas Urol Esp (Engl Ed). 2023 Sep;47(7):422-429. doi: 10.1016/j.acuroe.2023.02.001. Epub 2023 Feb 4.
The EAU proposed a progression and death risk classification in patients with biochemical recurrence after radical prostatectomy (PR).
To validate the EAU BCR-risk classification in our setting and to find factors related to progression and death.
Multicenter, retrospective, observational study including 2140 patients underwent RP between 2011 and 2015. Patients with BCR were identified and stratified in low risk (PSA-DT >1yr and pGS <8) or high-risk (PSA-DT ≤1yr or pGS ≥8) grouping. PSA and metastatic free survival (PSA-PFS, MFS), cancer specific survival (CSS) and overall survival (OS) were calculated (Kaplan Meier curves and log-rank test). Independent risk factors were identified (Cox regression).
427 patients experienced BCR (32.3% low-risk and 67.7% high-risk). Median PSA-PFS was 135,0 mo (95% CI 129,63-140,94) and 115,0 mo (95% CI 104,02-125,98) (p<0,001), for low and high-risk groups, respectively. There were also significant differences in MFS and OS. The EAU BCR risk grouping was independent factor for PSA-progression (HR 2.55, p 0.009). Time from PR to BCR, was an independent factor for metastasis onset (HR 0.43, 95% CI 0.18-0.99; p 0.044) and death (HR 0.17, 95% CI 0.26.0.96; 23 p 0.048). Differences in MFS (p 0.001) and CSS (p 0.004) were found for <12, ≥12-<36 and ≥36 months from PR to BCR. Others independent factors were early salvage radiotherapy and PSA at BCR.
High-risk group is a prognostic factor for biochemical progression, but it has a limited accuracy on MP and death in our setting. The inclusion of other factors could increase its predictive power.
欧洲泌尿外科学会(EAU)提出了一种在根治性前列腺切除术(PR)后生化复发患者中进展和死亡风险的分类。
在我们的环境中验证 EAU 的 BCR 风险分类,并找到与进展和死亡相关的因素。
这是一项多中心、回顾性、观察性研究,包括 2140 名于 2011 年至 2015 年间接受 PR 的患者。确定并将有 BCR 的患者分为低危组(PSA-DT >1 年且 pGS <8)或高危组(PSA-DT ≤1 年或 pGS ≥8)。计算 PSA 和无转移生存(PSA-PFS,MFS)、癌症特异性生存(CSS)和总生存(OS)(Kaplan-Meier 曲线和对数秩检验)。确定独立的危险因素(Cox 回归)。
427 名患者出现 BCR(低危组 32.3%,高危组 67.7%)。低危组和高危组的中位 PSA-PFS 分别为 135.0 个月(95%CI 129.63-140.94)和 115.0 个月(95%CI 104.02-125.98)(p<0.001)。MFS 和 OS 也存在显著差异。EAU 的 BCR 风险分组是 PSA 进展的独立因素(HR 2.55,p<0.009)。从 PR 到 BCR 的时间是转移发生(HR 0.43,95%CI 0.18-0.99;p<0.044)和死亡(HR 0.17,95%CI 0.26.0.96;p<0.048)的独立因素。从 PR 到 BCR 的时间<12、≥12-<36 和≥36 个月时,MFS(p<0.001)和 CSS(p<0.004)存在差异。其他独立因素是早期挽救性放疗和 BCR 时的 PSA。
高危组是生化进展的预后因素,但在我们的环境中对 MP 和死亡的准确性有限。纳入其他因素可以提高其预测能力。